Prior to the election, Biden was eager to talk about the existential threat that the president-elect posed to American democracy and the nightmarish future he said would follow if Trump ever returned ...

Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...

Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...

With Wegovy gaining acceptance for China in Q2 2024, this opens the door for Novo Nordisk to gain a foothold in a potentially ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

Novo Nordisk has launched Wegovy – its popular weight loss treatment – in China. China, with a population of 1.4 billion, has ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...

In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

Novo Nordisk A/S shares slipped again on Tuesday, briefly erasing what was left of this year’s lofty gains, as concerns ...